Ascletis Pharma (OTCMKTS:ASCLF – Get Free Report) is expected to be issuing its results after the market closes on Monday, August 31st. Analysts expect the company to post earnings of ($0.0294) per share and revenue of $4.0690 million for the quarter.
Ascletis Pharma Stock Down 3.0%
OTCMKTS:ASCLF opened at $1.30 on Friday. The firm’s 50 day moving average is $1.32 and its 200 day moving average is $1.70. Ascletis Pharma has a 12 month low of $1.07 and a 12 month high of $2.50.
Ascletis Pharma Company Profile
Ascletis Pharma (OTCMKTS:ASCLF) is a clinical‐stage biopharmaceutical company headquartered in Hangzhou, China, dedicated to the research, development and commercialization of therapies for viral and liver diseases. Since its founding in 2013, the company has built an integrated platform spanning small‐molecule discovery, process chemistry and clinical development. Ascletis is listed on the Hong Kong Stock Exchange and maintains facilities for both clinical research and commercial manufacturing in Mainland China.
The company’s core pipeline focuses on direct‐acting antiviral agents targeting hepatitis B virus (HBV), hepatitis C virus (HCV) and human immunodeficiency virus (HIV).
Read More
- Five stocks we like better than Ascletis Pharma
- 3 Financial Stocks Positioned for the Fed’s Next Move After Jackson Hole
- IREN’s AI Pivot Looks Real, But the Market Wanted a Faster Payoff After Earnings
- Boeing’s $131B F-15 Win: Mach 1 Momentum or Just Altitude?
- Okta Stock Surges 29%—Is $200 the Next Stop?
Receive News & Ratings for Ascletis Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ascletis Pharma and related companies with MarketBeat.com's FREE daily email newsletter.
